Cargando…

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, Antonio M., Prebet, Thomas, Itzykson, Raphael, Ramos, Fernando, Al-Ali, Haifa, Shammo, Jamile, Pinto, Ricardo, Maurillo, Luca, Wetzel, Jaime, Musto, Pellegrino, Van De Loosdrecht, Arjan A., Costa, Maria Joao, Esteves, Susana, Burgstaller, Sonja, Stauder, Reinhard, Autzinger, Eva M., Lang, Alois, Krippl, Peter, Geissler, Dietmar, Falantes, Jose Francisco, Pedro, Carmen, Bargay, Joan, Deben, Guillermo, Garrido, Ana, Bonanad, Santiago, Diez-Campelo, Maria, Thepot, Sylvain, Ades, Lionel, Sperr, Wolfgang R., Valent, Peter, Fenaux, Pierre, Sekeres, Mikkael A., Greil, Richard, Pleyer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/
https://www.ncbi.nlm.nih.gov/pubmed/28420120
http://dx.doi.org/10.3390/ijms18040837
_version_ 1783232998203719680
author Almeida, Antonio M.
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose Francisco
Pedro, Carmen
Bargay, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
author_facet Almeida, Antonio M.
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose Francisco
Pedro, Carmen
Bargay, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
author_sort Almeida, Antonio M.
collection PubMed
description Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
format Online
Article
Text
id pubmed-5412421
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54124212017-05-05 Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study Almeida, Antonio M. Prebet, Thomas Itzykson, Raphael Ramos, Fernando Al-Ali, Haifa Shammo, Jamile Pinto, Ricardo Maurillo, Luca Wetzel, Jaime Musto, Pellegrino Van De Loosdrecht, Arjan A. Costa, Maria Joao Esteves, Susana Burgstaller, Sonja Stauder, Reinhard Autzinger, Eva M. Lang, Alois Krippl, Peter Geissler, Dietmar Falantes, Jose Francisco Pedro, Carmen Bargay, Joan Deben, Guillermo Garrido, Ana Bonanad, Santiago Diez-Campelo, Maria Thepot, Sylvain Ades, Lionel Sperr, Wolfgang R. Valent, Peter Fenaux, Pierre Sekeres, Mikkael A. Greil, Richard Pleyer, Lisa Int J Mol Sci Article Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. MDPI 2017-04-14 /pmc/articles/PMC5412421/ /pubmed/28420120 http://dx.doi.org/10.3390/ijms18040837 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Almeida, Antonio M.
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose Francisco
Pedro, Carmen
Bargay, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_full Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_fullStr Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_full_unstemmed Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_short Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_sort clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: a retrospective multinational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/
https://www.ncbi.nlm.nih.gov/pubmed/28420120
http://dx.doi.org/10.3390/ijms18040837
work_keys_str_mv AT almeidaantoniom clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT prebetthomas clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT itzyksonraphael clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT ramosfernando clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT alalihaifa clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT shammojamile clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT pintoricardo clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT maurilloluca clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT wetzeljaime clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT mustopellegrino clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT vandeloosdrechtarjana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT costamariajoao clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT estevessusana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT burgstallersonja clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT stauderreinhard clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT autzingerevam clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT langalois clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT kripplpeter clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT geisslerdietmar clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT falantesjosefrancisco clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT pedrocarmen clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT bargayjoan clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT debenguillermo clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT garridoana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT bonanadsantiago clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT diezcampelomaria clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT thepotsylvain clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT adeslionel clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT sperrwolfgangr clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT valentpeter clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT fenauxpierre clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT sekeresmikkaela clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT greilrichard clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy
AT pleyerlisa clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy